Table of Contents August 28, 2023; Volume Issue supplement 1
Abazari, Mohammad Amin
- You have accessA Spatiotemporal Model to Determine Key Transport Mechanisms of the 18F-FMISO PET Radiopharmaceutical within Solid TumorsMohammad Amin Abazari, Faezeh Eydi, Madjid Soltani, Farshad Moradi Kashkooli and Arman RahmimJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P661;
- You have accessEffect of Heterogeneous Capillary Networks in Solid Tumors on Standardized 18F-FMISO Uptake Values: A Novel Spatiotemporal ModelMohammad Amin Abazari, Madjid Soltani, Farshad Moradi Kashkooli and Arman RahmimJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P814;
Abbaszadeh, Shiva
- You have accessβγ imaging: simultaneous detection of single-gamma and position-annihilation with CZT-based PET scannerShiva Abbaszadeh, Matthew Kupinski and Lars FurenlidJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1282;
Abbey, Craig
- You have accessComparison of performance between board-certified physicians and medically naive readers in a simple PET images detection taskPaul Kinahan, Sangtae Ahn, Scott Wollenweber, Kristen Wangerin, Darrin Byrd, Fatemeh Behnia, Amir Iravani, Murat Sadic, Delphine Chen and Craig AbbeyJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P183;
Abdalkadir,, Ahmed
- You have accessPSMA Radioligand Therapy Efficacy in Heavily pretreated mCRPC patients Treated at King Hussein Cancer Center in Jordan: a glimpse of theranostics in the Arab WorldAkram Al-Ibraheem, Feras Istatieh, Anwer Farah, Ula Al-Rasheed, Ahmed Abdalkadir,, Rahma Doudeen, Mohammed Shahait, Ramiz Abu-Hijlih, Alaa Abufara, Fadi Khreish and Samer SalehJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P662;
Abdalla, Ahmed
- You have accessOligometastatic Prostate Cancer as detected with PSMA PET/CT; Impact on Treatment StrategiesAtheel Alsagheer, Peter Temsah, Ahmed Abdalla, Lin Gu, Aileen Green, Razi Muzaffar and Medhat OsmanJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P380;
- You have access18F-PSMA PET/CT is Helpful in the Evaluation of Intermediate Risk Favorable and Low Risk Prostate Cancer Patients: A Pictorial EssayAileen Green, Peter Temsah, Atheel Alsagheer, Ahmed Abdalla, Lin Gu, Razi Muzaffar and Medhat OsmanJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1336;
Abdelhafez, Yasser
- You have accessDual time-point imaging of lymphoma adenopathy using total-body FDG PET/CTBimash Shrestha, Shashi Singh, Niloofaralsadat Motamedi, Thomas Werner, Lorenzo Nardo, Yasser Abdelhafez and Abass AlaviJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1444;
- You have accessTotal Body PET/CT versus Conventional PET/CT in Lymph Node Staging of Non-Small Cell Lung CancerRyan Lee, Yasser Abdelhafez, Yasamin Mohammad, Benjamin Spencer, Fatma Sen, Ramsey Badawi, Mohammad Madani, Lorenzo Nardo, David Cooke and Tianhong LiJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1333;
- You have accessImpact of Dual-blood Input Function on Kinetic Modeling of Lung Tumors using Total-Body PETYiran Wang, Yasser Abdelhafez, Benjamin Spencer, Rashmi Verma, Mamta Parikh, Nicholas Stollenwerk, Lorenzo Nardo, Terry Jones, Ramsey Badawi, Simon Cherry and Guobao WangJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P720;
- You have accessTotal-body compartmental visualization using kinetic modeling and the EXPLORER PET/CT systemYiran Wang, Benjamin Spencer, Yasser Abdelhafez, Mamta Parikh, Rashmi Verma, Lorenzo Nardo, Terry Jones, Ramsey Badawi, Simon Cherry and Guobao WangJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P736;
Abdelhameed, Dena
- You have accessEvaluation of residual on syringe pump delivery system for PLUVICTO™ (Lu-177 vipivotide tetraxetan)Ye Tian, Sony Thomas, Dena Abdelhameed, Nicholas Schertz, Michelle Coppens and Ryan AveryJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) TS14;
Abdelrahman, Ahmed
- You have accessBONE MARROW OPTIMIZATION DURING LU177-PSMA-617 TREATMENT: IS IT EFFECTIVE?Turgut Bora Cengiz, Ahmed Abdelrahman, Matteo Novello, Munir Ghesani and Nasrin GhesaniJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P147;
- You have accessCorrelation between the total osseus tumor volume and the development of hematologic toxicities in patients with metastatic castrate-resistant prostate cancer receiving 177Lu-PMSA-617.Ahmed Abdelrahman, Raksha Kulkarni, Rahman Akinlusi, Turgut Bora Cengiz, Matteo Novello, Bobby Liaw, William Oh, Somali Gavane, Munir Ghesani and Nasrin GhesaniJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P318;
- You have accessGuidance on Nuclear Medicine Theranostic Operations for 177Lu-PSMA Therapy; a single center experienceAhmed Abdelrahman, Myung Soon Lee, Ilda Bander, Dylan Magistro, Jacob Kamen, Virginia Corbett, Edward Wolin, Anthony Hafez, Somali Gavane, Munir Ghesani and Nasrin GhesaniJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P375;
- You have accessInitial Experience with Lutetium177-617 for Metastatic or Biochemically Recurrent Prostate Cancer: A Single Institution ReviewMatteo Novello, Ahmed Abdelrahman, Turgut Bora Cengiz, Raksha Kulkarni, Michael Berke, Rahman Akinlusi, Ilda Bander, Munir Ghesani and Nasrin GhesaniJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1168;
- You have accessIS ENZALUTAMIDE MORE EFFECTIVE FOR PROSTATE SPECIFIC ANTIGEN DECLINE COMPARED TO OTHER AGENTS PRIOR TO LU-177 PSMA THERAPY?Turgut Bora Cengiz, Anthony Hafez, Matteo Novello, Ahmed Abdelrahman, Raksha Kulkarni, Reema Goel, Somali Gavane, Munir Ghesani and Nasrin GhesaniJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P930;
- You have accessManagement Of Concomitant Prostate Cancer and Pancreatic Neuroendocrine Tumour: Role of Nuclear Medicine in therapeutic decision makingRaksha Kulkarni, Ahmed Abdelrahman, Munir Ghesani, Nasrin Ghesani, Edward Wolin, William Oh and Ilda BanderJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1440;
- You have access177Lu-PSMA-617 therapy in Chemotherapy Naïve patients: A single center experienceRaksha Kulkarni, Ahmed Abdelrahman, Matteo Novello, Turgut Bora Cengiz, Rahman Akinlusi, Ilda Bander, VAIBHAV PATEL, David Wise, Munir Ghesani and Nasrin GhesaniJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P356;
- You have accessDifference in Response to 177Lu-PSMA-617 Therapy in Patients with Predominantly Soft Tissue vs Osseous MetastasesRahman Akinlusi, Ahmed Abdelrahman, Turgut Bora Cengiz, Raksha Kulkarni, Matteo Novello, Reema Goel, Anthony Hafez, Somali Gavane, Munir Ghesani and Nasrin GhesaniJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1587;
- You have access177-Lu-PSMA-617 in a patient with stage 4 chronic kidney diseaseMichael Berke, Matteo Novello, Turgut Bora Cengiz, Ahmed Abdelrahman, David Wise, Munir Ghesani and Nasrin GhesaniJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P665;
Abdelrazek, Ahmad
- You have accessIntestinal obstruction in patients receiving peptide receptor radionuclide therapy for gastroentero-pancreatic neuroendocrine tumors: potential predictors and association with overall survivalMohamed Badawy, Geoffrey Johnson, Christopher Wee, Thorvardur R Halfdanarson, Ahmad Abdelrazek, Ann Packard, Manoj Jain, Matthew Thorpe and Ayse KendiJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P439;
- You have accessImaging response assessment with post 177Lu-PSMA-617 therapy SPECT-CT in metastatic castrate resistant prostate cancer: Adding value with a technologist driven post-processing workflowJaylee Messmer, Kaleb Soehl, Brian Burkett, Ayse Kendi, Geoffrey Johnson, Daniel Childs, Ahmad Abdelrazek, Ahmed Mahmoud, Rodrigo Rodrigues Pessoa, Reza Nabavizadeh, Eugene Kwon, Patrick Navin and Matthew ThorpeJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) TS16;
- You have accessIncomplete Lutetium-177 DOTATATE Treatment: Predictors of Therapy Completion, Reasons of Discontinuing Therapy, and the Role of Imaging During TherapyBrian Burkett, Matthew Thorpe, David Bartlett, Ahmad Abdelrazek, Michael Dick, Denise Gansen, Thorvardur R Halfdanarson, Timothy Hobday, Geoffrey Johnson, Brendan Lunn, Patrick Navin, Ann Packard and Ayse KendiJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P352;
- You have accessComparison of 18F-DCFPyL and 68Ga-PSMA-11 PET-CT for eligibility screening for 177Lu-PSMA-617 therapy in metastatic castrate resistant prostate cancer: Should insurers consider these methods equivalent?Kaleb Soehl, Jaylee Messmer, Brian Burkett, Ayse Kendi, Geoffrey Johnson, Daniel Childs, Ahmad Abdelrazek, Ahmed Mahmoud, Rodrigo Rodrigues Pessoa, Reza Nabavizadeh, Eugene Kwon, Patrick Navin and Matthew ThorpeJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) TS17;
- You have accessEarly Adverse Events, Emergency Room Visits and Hospitalizations After PSMA Based RLT: a Retrospective Analysis from Real World Theranostics PracticeAhmad Abdelrazek, Ahmed Mahmoud, Daniel Childs, Geoffrey Johnson, Fernando Quevedo, Brian Burkett, Derek Johnson, Corrie Bach, Reza Nabavizadeh, Rodrigo Rodrigues Pessoa, Matthew Thorpe, Eugene Kwon and Ayse KendiJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1018;
Abdollahi, Hamid
- You have accessLinear quadratic model in radiopharmaceutical therapies: Need for revisiting concepts and new modelsHamid Abdollahi, Babak Saboury, Carlos Uribe and Arman RahmimJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1465;
- You have accessRadiobiology of alpha and beta particles in radiopharmaceutical therapy: what to unlearn from external beam radiotherapyHamid Abdollahi, Carlos Uribe, Arman Rahmim and Babak SabouryJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1468;
- You have accessUsing the Cluster Gauss Newton Algorithm to Estimate Theranostic Pharmacokinetic Model ParametersNiloufar Zakariaei, Ali Fele Paranj, Hamid Abdollahi and Arman RahmimJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1449;
- You have accessTowards Non-Tracer Kinetic Modeling: Our Past Returning Through the FutureArman Rahmim, Hamid Abdollahi, Ali Fele Paranj, Kyung-Nam Lee, Babak Saboury and Carlos UribeJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1447;
- You have accessIt is the matter of time: highlighting the difference between biological effect of continuous versus fractionated radiation to improve optimization of radiopharmaceutical therapyHamid Abdollahi, Babak Saboury, Xinchi Hou, Carlos Uribe and Arman RahmimJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1460;
- You have accessIn Silico Investigation of The Effect of Multi-Bolus Injections in Absorbed Doses to Organs and Tumors in Radiopharmaceutical TherapiesAli Fele Paranj, Carlos Uribe, Hamid Abdollahi, Elaheh Mollaheydar, Niloufar Zakariaei, Md Shahriar Rahim Siddiqui, Babak Saboury and Arman RahmimJournal of Nuclear Medicine June 1, 2023, 64 (supplement 1) P1422;
